№ files_lp_4_process_1_51757
File format: docx
Character count: 9942
File size: 144 KB
Comprehensive project charter defining objectives, scope, deliverables, success criteria, milestones, budget, and stakeholder responsibilities for a complex or high-risk initiative.
Year:
2026
Organization / Department:
UTM Campus PMO
Document Type:
Project Charter
Intended Audience:
Project Managers, Sponsors, Project Owners, Executives
Project ID:
Provided by PMO
Project Name:
[Enter name of project]
Project Sponsor:
[Name], [Position], [Department]
Project Owner:
[Name], [Position], [Department]
Project Manager:
[Name], [Position], [Department]
Version:
1.0
Date of Approval:
[Insert Date]
Revision History:
0.1–1.0
Budget:
[Enter estimated budget]
Scope:
High-complexity or high-risk project implementation
Deliverables:
Defined project outputs including transition plans, communication plans, and lessons learned register
Milestones:
Key project phases and expected completion dates
Key Stakeholders:
Project Sponsor, Project Manager, Project Owner, Project Team members
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Region / city:
Canberra
Subject:
Anticoagulant medicines, High-Risk Medicines
Document type:
Procedure
Organization / institution:
Canberra Health Services
Target audience:
Health professionals involved in prescribing, dispensing, and administering anticoagulants
Context:
This document provides guidelines on the safe management of high-risk anticoagulant medicines in Canberra Health Services to prevent prescription, dispensing, and administration errors.
Note:
Year
Region / city:
Canberra
Topic:
High-Risk Medicines, Insulin Administration
Document Type:
Procedure
Institution:
Canberra Health Services
Target Audience:
CHS Employees (Medical, Nursing, Midwifery, Pharmacy, Allied Health)
Year:
2023
Region / City:
Victoria
Subject:
Medication Safety, High-Risk Medicines
Document Type:
Guidance
Organization:
Victorian Department of Health
Author:
eHealth High Risk Medicine Safety Advisory Group
Target Audience:
Healthcare professionals, Clinical staff
Period of validity:
Ongoing
Approval Date:
2023
Date of Changes:
None
Year:
Not specified
Region / City:
Australia
Topic:
Health, Safety, Environment
Document Type:
Framework / Policy Guidance
Organization:
Telstra
Audience:
Suppliers of services and high-risk products
Scope:
Suppliers of services and high-risk products to Telstra
References:
Telstra HSE Standards, AS/NZ 3745
Attachments:
Definitions (Attachment 1)
Requirements:
Legal and contractual obligations of suppliers, mandatory HSE elements including Asbestos, Gas Detection, Special Work Locations, Electromagnetic Energy
Emergency Planning:
Compliance with AS/NZ 3745 for facilities management
Monitoring:
Managed and reviewed by Telstra designated contact, network induction mandatory for suppliers and visitors
Risk Management:
Includes hazard identification, inspections, risk assessment, and control measures
Environmental Considerations:
Energy impact, recycling, waste management, visual and flora/fauna protection
Note:
Year
Subject:
Travel and safety regulations
Document Type:
Waiver Application
Organization / Institution:
University of Connecticut
Target Audience:
University students participating in travel programs
Year:
2024
Region / city:
Australia
Theme:
Medical devices, Clinical trials
Document type:
Guidance
Institution:
Therapeutic Goods Administration (TGA)
Target audience:
Clinical trial sponsors, Medical device manufacturers
Effective period:
From 20 March 2024
Approval date:
14 March 2024
Changes date:
14 March 2024
Document type:
Emergency rescue plan
Scope:
High-risk work activities
Related high-risk work:
Confined space entry; use of safety harness; excavation and trenching; energised fault finding
Emergency phone numbers:
000; 112; (07) 3270 4040
Country:
Australia
Region:
Queensland
Emergency communication:
Phone; radio channel (if applicable)
Rescue scenarios:
Engulfment; falls; hazardous atmosphere; hazardous chemicals; fire; electrical
Required rescue equipment:
Harness; first aid kit; breathing apparatus; rescue lines; stretchers; oxygen resuscitation equipment; tripod or davit; lighting; firefighting equipment; gas detector; defibrillator; ventilation equipment; crane
Participants:
Rescue party members; spotters; qualified rescuers
Preconditions:
Rescue equipment set up and tested prior to work; briefing completed before commencement
Intended audience:
Workers and rescue personnel involved in high-risk work
Year:
2021
Region / city:
Australia
Theme:
Biosecurity
Document type:
Regulatory list
Organization / institution:
Australian Government Department of Agriculture, Water and the Environment
Target audience:
Importers and stakeholders in agriculture and biosecurity
Period of validity:
Not specified
Approval date:
Not specified
Date of amendments:
Not specified
Note:
Year
Contextual description:
A research paper providing advanced imaging analysis methods for refining risk assessment in high-risk neuroblastoma patients.
Document Type:
Category 1 submission for Authority Required (Written) listing
Medicine:
Eflornithine (Ifinwil®) 250 mg tablet
Active Ingredient:
Eflornithine (as hydrochloride)
Sponsor:
Norgine Pty Ltd
Regulatory Authority:
Therapeutic Goods Administration (TGA)
Advisory Body:
Pharmaceutical Benefits Advisory Committee (PBAC)
Program:
Section 100 – Highly Specialised Drugs Program
Schedule:
General Schedule (Code GE – Schedule 85)
Indication:
High-risk neuroblastoma in patients aged 1 year and older in remission after prior therapy
Population:
Patients ≥1 year with high-risk neuroblastoma meeting INRG, COG, or SIOPEN criteria
Treatment Phase:
Initial and Continuing Treatment
Comparator:
Standard of care (follow-up and monitoring)
Clinical Outcomes:
Event-free survival, overall survival, safety
Dosage Form:
250 mg oral tablet
Treatment Duration:
Up to 27 cycles (2 years) or until disease progression
Orphan Drug Designation:
Granted 7 December 2022
Submission Pathway:
TGA/PBAC Parallel Process
Restriction Type:
Authority Required (Full assessment – written)
Prescriber Type:
Medical Practitioners (paediatric oncologist or haematologist for initiation)
Year:
2023
Region / City:
N/A
Subject:
Medical Research
Document Type:
Research Supplementary Figures
Institution:
N/A
Author:
N/A
Target Audience:
Medical Professionals
Action Period:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Context:
A set of supplementary figures for a study on the risk of Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) based on high-risk threshold values of hs-CRP and LDL-C, categorizing patients by these values and analyzing survival outcomes.
Year:
2026
Region:
United States
Subject:
Obstetric care, community birth
Document Type:
Clinical guideline
Issuing Organization:
Oregon Health Authority
Author:
Health Evidence Review Commission (HERC)
Target Audience:
Healthcare providers, midwives, obstetricians
Scope:
Prenatal, intrapartum, and postpartum care for low-risk pregnancies
High-Risk Conditions:
Detailed list of maternal, fetal, and pregnancy conditions requiring hospital transfer or consultation
Reference:
HERC Coverage Guidance
Note:
Document Number
Document Type:
Internal Audit Charter
Organization:
COMPANY NAME
Responsible Committee:
Audit and Risk Committee
References:
King Report on Corporate Governance (King III), COMPANY NAME Board Charter
Scope:
All internal audit activities
Staffing:
In-house permanent employee and co-sourced registered auditors
Standards:
Standards for the Professional Practice of Internal Auditing, IIA Code of Ethics
Jurisdiction:
Clay County, Missouri
Type of document:
Charter
Subject matter:
Opioid settlement fund governance
Purpose:
Advisory oversight and recommendations on opioid settlement fund allocation
Funding source:
Opioid Settlement Agreement
Total settlement amount:
Approximately $1,444,623.26
Funding period:
18 years
Annual allocation:
Approximately $80,000
Governing body:
Clay County Commission
Advisory body:
Clay County Opioid Settlement Task Force
Membership size:
9 members
Appointing authority:
Presiding Commissioner with consent of the Governing Body
Meeting openness:
Open to the public
Public notice law:
Missouri Open Records Act
Meeting location:
Clay County Administration, 1 Courthouse Square, Liberty, Missouri
Reporting requirement:
Formal report and proposed plan submitted to the Commission
Termination condition:
Approval of an opioid settlement utilization plan by the Clay County Commission
Year:
2020
Region / City:
Queensland
Subject:
Youth Engagement, Government Policy, Aboriginal and Torres Strait Islander Youth
Document Type:
Charter
Organization / Institution:
Queensland Government
Author:
Queensland Government
Target Audience:
Young people, government officials, community organizations
Effective Period:
Ongoing
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2020
Region / City:
Atlanta, Ga.
Topic:
Education, Grants
Document Type:
Press Release
Organization / Institution:
Chick-fil-A, Inc., State Charter Schools Commission of Georgia, State Charter Schools Foundation of Georgia
Author:
Danielle Williams
Target Audience:
General Public, Educational Institutions
Period of Action:
2021
Approval Date:
December 17, 2020
Modification Date:
None
Context:
Press release announcing the 2021 True Inspiration Awards, which granted financial support to two state charter schools for their innovative educational approaches.
Note:
Year
Type of Document:
Charter / Standard Operating Procedure
Study Phase:
Clinical Trial
Responsibilities:
Participant safety monitoring, data quality assessment, trial progress evaluation
Membership:
DSMB Chair, Voting Members, Independent Medical Monitor (if applicable)
Conflict of Interest Policy:
Disclosure and management of real or apparent conflicts
Meeting Requirements:
Quorum and attendance rules
Stopping Criteria:
Safety concerns and trial halting conditions